Navigation Links
Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
Date:5/17/2012

BALTIMORE, May 16, 2012 /PRNewswire/ -- In an effort to voice concern on biosimilars pathways for patients with primary immunodeficiency diseases (PIDD), the Immune Deficiency Foundation (IDF) offered oral testimony at last week's U.S. Food and Drug Administration (FDA) public hearing on draft guidance of biosimilars products. IDF urged the FDA to exempt immunoglobulin (Ig) therapies from the biosimilars pathways in order to protect the safety of patients with PIDD.

PIDD occurs in people born with an immune system that is either absent or hindered in its ability to function, causing an array of illnesses. Many of these patients require Ig therapy, a biologic medicine, for long-term management. Ig therapies are derived from human blood product, or plasma, and can differ in terms of processing and end composition.

"The FDA should restrict Ig therapies from the biosimilars pathways until the science advances significantly," said Marcia Boyle, president and founder, IDF. "Patients with primary immunodeficiency diseases depend on frequent antibody replacements with Ig therapy in order to fight infections."

The FDA recognizes each Ig brand as unique with no generic equivalent— Ig products are not clinically interchangeable. Current science cannot demonstrate that two products will provide the exact same clinical results for a large number of patients or that switching patients from one product to another will pose no additional risks.

Boyle's testimony urged the FDA to follow the example set by the European Medicines Agency and exempt Ig therapy from the biosimilars pathway, or to at the least require that biosimilars products undergo clinical trials to determine whether a proposed interchangeable therapy will offer patients the same clinical outcome. Additionally, Boyle requested that the FDA prohibit automatic substitution of a biosimilars with an original biologic.

"We believe the FDA's foremost responsibility
'/>"/>

SOURCE Immune Deficiency Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Peptimmune Presentations at Upcoming Events
9. Protein-printing technique gives snapshots of immune system defense
10. Visualizing asthma-causing immune cells at work
11. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 2014 ... Industry” is a professional and in-depth research ... report provides basic Seaweed Fertilizer information, including ... chain structure as well as industry overview. ... including domestic market as well as global ...
(Date:8/21/2014)... August 21, 2014 The College of ... private college in the Mid-Hudson Region to be designated ... begin accepting applications from qualified “high-technology” businesses that align ... very pleased to have been selected for the START-UP ... transformative initiative to stimulate economic development in New York ...
(Date:8/21/2014)... HONG KONG , Aug. 21, 2014  China Cord ... today announced its plan to release financial results for ... August 28, 2014, after market close in the US.  ... call at 8:00 a.m. ET on Friday, August 29, ... brief overview of the Company,s recent developments, followed by ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... ... - Aggressive acquisition ... Worldwide Clinical,Trials, Inc.("WCT"), formed by Dr. Neal R. Cutler and a team ... research organization with the announcement that it has closed the,acquisition of MediQuest, ...
... Cepheid (Nasdaq:,CPHD) today announced the appointment ... Associated Infections, Fred Tenover, Ph.D., as,Senior Director ... as a liaison,with the Infection Control community ... Consortium program., "The objective of the ...
... July 9 Par,Pharmaceutical Companies, Inc. (NYSE: PRX ... and 25mg meclizine HCl tablets immediately. At,this time, Par ... product., Par marketed meclizine prior to an explosion ... Par has since qualified a new API source and,received ...
Cached Biology Technology:Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization 2Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization 3Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 2Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 3Par Pharmaceutical to Launch meclizine HCL Tablets 2
(Date:8/21/2014)... they are the ultimate source of all organic matter ... on algae, too, to suck up climate-warming carbon dioxide ... of the ocean. Now, by using a combination of ... that viruses infecting those algae are driving the life-and-death ... stays essentially the same, and this has important implications ...
(Date:8/21/2014)... researchers from Beth Israel Deaconess Medical Center (BIDMC ) ... Most Influential Scientific Minds 2014," a comprehensive list ... web resource for science metrics and research performance analysis. ... most influential "are performing and publishing work that their ... science," according to a Thomson Reuters statement. Researchers were ...
(Date:8/21/2014)... 2014 , WHERE: , San Diego Convention ... 92101 , WHAT: , Invited and platform ... research in human genetics. Examples of sessions include: ... rare genetic variants in health and disease, the ... sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , Crowdsourced ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3American Society of Human Genetics 2014 Annual Meeting 2
... Researchers from the John Innes Centre in Norwich, Great ... the FLORA project, have obtained genetically modified tomatoes rich ... class of flavonoids. These tomatoes, added to the diet ... extending the mice lifespan. The research has been published ...
... launcher that shall carry ESA,s GOCE Earth Explorer satellite ... in the guidance and navigation system of the launcher,s ... during the spacecraft,s launch preparation tests on 7 September ... of the launch. , The cause of the anomaly ...
... PHILADELPHIA Frank L. Meyskens, Jr., M.D., one ... chemoprevention, has been selected to receive the seventh ... Foundation Award for Excellence in Cancer Prevention Research. ... scientist for seminal contributions to the field of ...
Cached Biology News:Purple tomatoes: The richness of antioxidants against tumors 2Purple tomatoes: The richness of antioxidants against tumors 3Meyskens honored with AACR-Prevent Cancer Foundation award 2